CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00313-07v1
14/12/1592    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mansour, D.
Right arrow Articles by el Harith, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mansour, D.
Right arrow Articles by el Harith, A.
Clinical and Vaccine Immunology, December 2007, p. 1592-1595, Vol. 14, No. 12
1071-412X/07/$08.00+0     doi:10.1128/CVI.00313-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Use of a Newly Developed β-Mercaptoethanol Enzyme-Linked Immunosorbent Assay To Diagnose Visceral Leishmaniasis in Patients in Eastern Sudan{triangledown}

Durria Mansour, Elfadil M. Abass, Mohamed el Mutasim,{dagger} Abdelhafeiz Mahamoud, and Abdallah el Harith*

Ahfad University for Women, P.O. Box 167, Omdurman, Sudan

Received 26 July 2007/ Returned for modification 12 September 2007/ Accepted 2 October 2007

Corroboration of serology results is essential for restricting the risk of inappropriate antileishmanial prescription. A direct agglutination test (DAT) and a recently developed β-mercaptoethanol-modified enzyme-linked immunosorbent assay (β-ME ELISA) based on the use of antigen prepared as described for the DAT were applied to 416 sera from two Sudanese populations with and without clinical evidence of visceral leishmaniasis (VL). Of 285 sera with the lowest antileishmanial DAT titers (≤1:100 to 1:1,600), 270 (94.7%) scored comparable minimum β-ME ELISA absorbance values (≤0.1 to 0.26). In 117 sera that demonstrated the highest DAT titers (1:12,800 to ≥1:25,600), 86 (73.5%) scored maximum (0.81 to ≥1.35) and 30 (25.6%) medium (0.27 to 0.80) β-ME ELISA absorbance values. VL diagnosis was established for 142 (44.1%) patients in the VL-symptomatic group (n = 322), based on positive microscopy for Leishmania donovani in lymph node aspirates or positive DAT (titer, ≥1:3,200). Of the 125 sera from the symptomatic patients for whom microscopy was positive for VL, 111 (88.8%) had comparable positive DAT and β-ME ELISA readings. In all 17 sera from the symptomatic DAT-positive patients for whom leishmaniasis was not established by microscopy but who responded favorably to antileishmanial therapy, absorbance values (≥0.27) indicative of VL were obtained by β-ME ELISA. Of 197 symptomatic patients for whom microscopy was negative for VL, 172 (87.3%) tested negative in β-ME ELISA and 180 (91.4%) in DAT. Based on the high reliability demonstrated here for VL detection, β-ME ELISA fulfills the requirement of confirming DAT results in patients manifesting suspected VL.


* Corresponding author. Present address: Wijngaard 155, 8212 CJ Lelystad, The Netherlands. Phone and fax: 31 320 235 229. E-mail: harith17{at}yahoo.com

{triangledown} Published ahead of print on 17 October 2007.

{dagger} Present address: Laboratory Department, Aljouf College of Health Sciences for Boys, Sakaka, Aljouf, Kingdom of Saudi Arabia.


Clinical and Vaccine Immunology, December 2007, p. 1592-1595, Vol. 14, No. 12
1071-412X/07/$08.00+0     doi:10.1128/CVI.00313-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.